$XBI $127.74 +4.6%
Covid Updates
$BNTX +9.6% Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older source
$DVAX +14.4% Medigen Vaccine Biologics Announces Launch of Its COVID-19 Vaccine MVC-COV1901 Adjuvanted with Dynavax's CpG 1018 Adjuvant. source
$VALN +5.0% Valneva Commences Rolling Submission to MHRA for its Inactivated, Adjuvanted COVID-19 Vaccine. source
Pipeline Updates
$BMY -0.38% U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD) source
$AMNL -14.0% Amneal Announces Virtual Event to Discuss Initial Data from Pivotal Phase 3 Study of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations source
$PTCT +3.5% PTC Therapeutics Announces Waylivra™ Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome source
$TBPH +0.9% Theravance Biopharma, Inc. Announces Top-line Results From Phase 2b Dose-finding Induction Study Of Izencitinib In Patients With Ulcerative Colitis source
$SRNE +7.0 % Sorrento Publishes Positive Initial Results of SOFUSA® Lymphatic Drug Delivery System in a Phase 1b Rheumatoid Arthritis Study Using Enbrel source
$CARA +4.2% Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients source
$VIR +3.4%Vir Biotechnology Announces First Marketing Authorization for its First Commercial Product, Sotrovimab, Granted in Australia. source
$XERS +21.4% Xeris Pharmaceuticals Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke® Kit for the Treatment of Severe Hypoglycemia. source
$VIRX +7.0% Viracta Therapeutics Reacquires Exclusive Development and Commercialization Rights for its All-Oral Combination Therapy in China. source
$NGM +3.0% NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research. source
$ATHA +6.0% Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer’s Disease Summit. source
$RDHL +3.0% RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn's. source
$BLU +8.5% BELLUS Health to Report Additional RELIEF Data in an Oral Presentation at the European Respiratory Society International Congress 2021. source
$FHTX +4.4% Foghorn Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of FHD-609. source
$KZR +13.2% Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyositis and Dermatomyositis. source
$GKOS +2.0% Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent® Technologies. source
$TXMD +7.1% TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector. source
$KALV +7.8% KalVista Pharmaceuticals Provides Progress Update on Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema. source
$AXSM +15.0% Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder. source
$AMRN +7.2% Amarin Reports Data from REDUCE-IT® Showing VASCEPA®/VAZKEPA (Icosapent Ethyl) Significantly Reduces Ischemic Events in Patients with Prior Heart Attacks Presented in Late Breaking Science Session at ESC Congress 2021, Organized by the European Society of. source
Market update
$TRIL +188.0% Pfizer to Acquire Trillium Therapeutics Inc. source
Posted by FS/JM
Comments